We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Ecolab (ECL) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Ecolab (ECL - Free Report) is expected to reveal quarterly earnings of $1.54 per share, indicating an increase of 21.3% compared to the year-ago period. Analysts forecast revenues of $3.96 billion, representing an increase of 7.8% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Ecolab metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Sales- Global Institutional & Specialty (Fixed currency)' should arrive at $1.26 billion. The estimate suggests a change of +9.3% year over year.
The combined assessment of analysts suggests that 'Sales- Global Industrial (Fixed currency)' will likely reach $1.88 billion. The estimate suggests a change of +0.9% year over year.
The consensus among analysts is that 'Sales- Global Healthcare and Life Sciences (Fixed currency)' will reach $413.06 million. The estimate indicates a change of -4.2% from the prior-year quarter.
Analysts' assessment points toward 'Sales- Other (Fixed currency)' reaching $368.96 million. The estimate indicates a change of +4.1% from the prior-year quarter.
Analysts expect 'Sales- Corporate (Fixed currency)' to come in at $18.67 million. The estimate indicates a change of -32.6% from the prior-year quarter.
The average prediction of analysts places 'Operating Income- Global Industrial (Fixed currency)' at $309.78 million. Compared to the current estimate, the company reported $283.80 million in the same quarter of the previous year.
The consensus estimate for 'Operating Income- Global Institutional & Specialty (Fixed currency)' stands at $226.69 million. The estimate compares to the year-ago value of $172 million.
Analysts predict that the 'Operating Income- Other (Fixed currency)' will reach $67.73 million. Compared to the current estimate, the company reported $59.20 million in the same quarter of the previous year.
According to the collective judgment of analysts, 'Operating Income- Global Healthcare and Life Sciences (Fixed currency)' should come in at $43.11 million. The estimate compares to the year-ago value of $67.70 million.
Shares of Ecolab have demonstrated returns of +2.8% over the past month compared to the Zacks S&P 500 composite's +6.5% change. With a Zacks Rank #3 (Hold), ECL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Ecolab (ECL) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Ecolab (ECL - Free Report) is expected to reveal quarterly earnings of $1.54 per share, indicating an increase of 21.3% compared to the year-ago period. Analysts forecast revenues of $3.96 billion, representing an increase of 7.8% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Ecolab metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Sales- Global Institutional & Specialty (Fixed currency)' should arrive at $1.26 billion. The estimate suggests a change of +9.3% year over year.
The combined assessment of analysts suggests that 'Sales- Global Industrial (Fixed currency)' will likely reach $1.88 billion. The estimate suggests a change of +0.9% year over year.
The consensus among analysts is that 'Sales- Global Healthcare and Life Sciences (Fixed currency)' will reach $413.06 million. The estimate indicates a change of -4.2% from the prior-year quarter.
Analysts' assessment points toward 'Sales- Other (Fixed currency)' reaching $368.96 million. The estimate indicates a change of +4.1% from the prior-year quarter.
Analysts expect 'Sales- Corporate (Fixed currency)' to come in at $18.67 million. The estimate indicates a change of -32.6% from the prior-year quarter.
The average prediction of analysts places 'Operating Income- Global Industrial (Fixed currency)' at $309.78 million. Compared to the current estimate, the company reported $283.80 million in the same quarter of the previous year.
The consensus estimate for 'Operating Income- Global Institutional & Specialty (Fixed currency)' stands at $226.69 million. The estimate compares to the year-ago value of $172 million.
Analysts predict that the 'Operating Income- Other (Fixed currency)' will reach $67.73 million. Compared to the current estimate, the company reported $59.20 million in the same quarter of the previous year.
According to the collective judgment of analysts, 'Operating Income- Global Healthcare and Life Sciences (Fixed currency)' should come in at $43.11 million. The estimate compares to the year-ago value of $67.70 million.
View all Key Company Metrics for Ecolab here>>>
Shares of Ecolab have demonstrated returns of +2.8% over the past month compared to the Zacks S&P 500 composite's +6.5% change. With a Zacks Rank #3 (Hold), ECL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>